Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective decreased by Bank of America from $13.00 to $11.00 in ...

It's been a mediocre week for Myriad Genetics, Inc. (NASDAQ:MYGN) shareholders, with the stock dropping 11% to US$10.42 in the week since its latest annual results. The statutory results were mixed ...

Piper Sandler lowered the firm’s price target on Myriad Genetics (MYGN) to $11.50 from $14 following quarterly results. The firm keeps a ...

BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $11 from $13 and keeps an Underperform rating on the shares after Myriad ...

Myriad Genetics (NASDAQ:MYGN) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of ...

Myriad Genetics (NASDAQ:MYGN – Free Report) had its price objective cut by Piper Sandler from $14.00 to $11.50 in a research note issued to investors on Tuesday morning,Benzinga reports.

Shared investments between research institutions and the government are essential for the health, prosperity and future of ...

UPPSALA, SE / ACCESS Newswire / March 5, 2025 /Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in ...

Burning Rock Biotech Limited’s BNR share price has dipped by 13.08%, which has investors questioning if this is right time to buy.

UPPSALA, SE / ACCESS Newswire / March 5, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, has signed a collaboration agreement with Eurobio Scie ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...